Ocugen (OCGN) said Thursday that the first patient has been dosed in the phase 1 clinical trial of OCU200 for diabetic macular edema.
The trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal injection in three cohorts, the biotechnology company said.
Ocugen said it plans to seek approval for OCU200 as a first-line therapy for diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration.
Price: 0.72, Change: -0.01, Percent Change: -0.86
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。